Oncotarget · 2015 · 49 citations · 35 references
MedicineCancer BiologyOncologyCytoskeletonMolecular OncologyTumor ProgressionCell-cycle DysregulationMicrotubule-associated ProteinsMitotic InhibitorsOncogenic ProliferationProtein Kinase CascadesTargeted Cancer TherapyCancer Cell Proliferation InhibitionCdk InhibitorsKinase InhibitorsMicrotubule Array OrganizationMicrotubule Network OrganizationMicrotubule PolymerizationMicrotubule Polymerization DisruptionMitotic Microtubule Dynamics
// Katerina Mardilovich 1 , Mark Baugh 1 , Diane Crighton 1 , Dominika Kowalczyk 1 , Mads Gabrielsen 1 , June Munro 1 , Daniel R. Croft 1 , Filipe Lourenco 1 , Daniel James 1 , Gabriella Kalna 1 , Lynn McGarry 1 , Oliver Rath 1 , Emma Shanks 1 , Mathew J. Garnett 2 , Ultan McDermott 2 , Joanna Brookfield 3 , Mark Charles 3 , Tim Hammonds 4 and Michael F. Olson 1 1 Cancer Research UK Beatson Institute, Garscube Estate, Glasgow, UK 2 Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK 3 Cancer Research Technology Discovery Laboratories, Jonas Webb Building, Babraham Research Campus, Cambridge, UK 4 Cancer Research Technology Discovery Laboratories, London Bioscience Innovation Centre, London, UK Correspondence to: Michael F. Olson, email: // Keywords : cytoskeleton, microtubule, inhibitor, LIMK, kinase Received : June 23, 2015 Accepted : October 01, 2015 Published : November 03, 2015 Abstract The actin and microtubule cytoskeletons are critically important for cancer cell proliferation, and drugs that target microtubules are widely-used cancer therapies. However, their utility is compromised by toxicities due to dose and exposure. To overcome these issues, we characterized how inhibition of the actin and microtubule cytoskeleton regulatory LIM kinases could be used in drug combinations to increase efficacy. A previously-described LIMK inhibitor (LIMKi) induced dose-dependent microtubule alterations that resulted in significant mitotic defects, and increased the cytotoxic potency of microtubule polymerization inhibitors. By combining LIMKi with 366 compounds from the GSK Published Kinase Inhibitor Set, effective combinations were identified with kinase inhibitors including EGFR, p38 and Raf. These findings encouraged a drug discovery effort that led to development of CRT0105446 and CRT0105950, which potently block LIMK1 and LIMK2 activity in vitro , and inhibit cofilin phosphorylation and increase αTubulin acetylation in cells. CRT0105446 and CRT0105950 were screened against 656 cancer cell lines, and rhabdomyosarcoma, neuroblastoma and kidney cancer cells were identified as significantly sensitive to both LIMK inhibitors. These large-scale screens have identified effective LIMK inhibitor drug combinations and sensitive cancer types. In addition, the LIMK inhibitory compounds CRT0105446 and CRT0105950 will enable further development of LIMK-targeted cancer therapy.
35
TM4: A Free, Open-Source System for Microarray Data Management and Analysis
A Saeed, Vasily Sharov, Joseph White et al. · BioTechniques · 2003 · 5K citations · Full text
Systematic identification of genomic markers of drug sensitivity in cancer cells
Mathew J. Garnett, Elena J. Edelman, Sonja J. Heidorn et al. · Nature · 2012 · 2.6K citations · Full text
Medicine, Cancer Biology, Oncology +16
A quantitative analysis of kinase inhibitor selectivity
Mazen W. Karaman, Sanna Herrgård, Daniel K. Treiber et al. · Nature Biotechnology · 2008 · 2.4K citations
A small molecule–kinase interaction map for clinical kinase inhibitors
Miles A. Fabian, William Biggs, Daniel K. Treiber et al. · Nature Biotechnology · 2005 · 1.9K citations · Full text